BioXcel Therapeutics (BTAI) Depreciation & Amortization (CF) (2017 - 2026)

BioXcel Therapeutics' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $58000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 23.68% year-over-year to $58000.0; the TTM figure through Mar 2026 stood at $282000.0 (down 8.14% YoY), while the FY2025 annual figure was $300000.0, down 2.91% from the prior year.
• Depreciation & Amortization (CF) was $58000.0 for Q1 2026 at BioXcel Therapeutics, down from $74000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $85000.0 in Q3 2022 to a low of $58000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $77176.5 across 5 years, with a median of $77000.0 in 2022.
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) increased 18.46% in 2022, then decreased 23.68% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $81000.0 in 2022, then fell by 3.7% to $78000.0 in 2023, then retreated by 1.28% to $77000.0 in 2024, then slipped by 3.9% to $74000.0 in 2025, then retreated by 21.62% to $58000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $58000.0 (Q1 2026), $74000.0 (Q4 2025), and $75000.0 (Q3 2025), per Business Quant data.